GlycoEra AG

Glycobiology and protein degradation

GlycoEra AG is a biotechnology company building a high-value pipeline of medicines in precision immunology based on deep expertise in glycobiology and protein degradation. GlycoEras innovative CustomGlycan platform enables the design, engineering, and development of novel biologics for a broad range of indications. GlycoEra is advancing a range of assets toward human clinical studies.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

28.05.2025

GlycoEra raises USD 130 Million Series B to advance targeted autoimmune therapies (venturelab.swiss)

27.05.2025

GlycoEra AG raises $130 Million to advance therapies for autoimmune diseases (startupticker.ch)

08.01.2024

Bristol Myers Squibb invests in GlycoEra (startupticker.ch)

12.05.2023

Startups welcome seasoned industry leaders to their board (startupticker.ch)

27.07.2022

Startups rely on seasoned board members’ expertise (startupticker.ch)

09.05.2022

C-Level managers for tech startups (startupticker.ch)

12.11.2021

GlycoEra seals series A financing round at CHF 45 million (startupticker.ch)

19.01.2021

LimmaTech launches spin-out for drug development (startupticker.ch)

Last Tweets

Tweets by TwitterDev

No milestones

No Jobs

No videos and documents

TOP 100 Swiss Startup Award

The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.

TOP 100 Swiss Startups 2025 TOP 100 Swiss Startups 2024 TOP 100 Swiss Startups 2023 TOP 100 Swiss Startups 2022

Website